# LITS earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/LITS) · [Earnings tab](https://www.lopjlb.com/stock/LITS?tab=earnings) Updated: 2026-09-29T09:31:23 Quarters analyzed: 7 ## Cross-quarter narrative Across 7 calls for LITS, management tone moved from +0.00 (2017 Q4) to +0.60 (2023 Q4). Latest guidance stance: maintained. Latest desk line: MEI Pharma, after terminating its Infinity merger, is focused on two early‑stage oncology candidates—voruciclib and ME‑344—with data readouts slated for early 2024 and a cash runway of at least 12 months, while navigating stockholder activism and early‑phase clinical risk. ## Latest CallCard · Q4 MEI Pharma, after terminating its Infinity merger, is focused on two early‑stage oncology candidates—voruciclib and ME‑344—with data readouts slated for early 2024 and a cash runway of at least 12 months, while navigating stockholder activism and early‑phase clinical risk. **Guidance:** maintained — Management reaffirmed that cash balances are sufficient to fund operations for at least the next 12 months, covering current Phase 1 work. **Tone:** mgmt 0.6 · Q&A pressure 0.4 · divergence 0.3 Management expressed optimism about the two programs and their market potential in prepared remarks. ### Demand visibility Limited visibility beyond current Phase 1 programs; data readouts expected early 2024. Analysts asked about cash runway and future revenue; management indicated no further collaboration revenue and emphasized upcoming clinical readouts. ### Margins / costs Not addressed in the call. The transcript contains no specific discussion of margins or cost structure. ### Capital allocation Cash allocated to Phase 1 programs and winding down of other trials. $100.7 M cash on hand; $52.5 M R&D spend with $26 M tied to zandelisib wind‑down; Q4 R&D reflects wind‑down of COASTAL and TIDAL studies. ### Milestones - **Voruciclib Phase 1 data readout** [on_track]: Readout planned for early 2024, focusing on safety, PK and biomarker (MCL‑1, MYC) data. - **ME‑344 Phase 1b data readout** [on_track]: First‑half‑2024 readout of safety and efficacy from the initial 20‑patient cohort in metastatic colorectal cancer. - **Zandelisib trial wind‑down** [delivered]: Trial expected to conclude around October 2023 with minimal remaining expense. - **COASTAL and TIDAL studies wind‑down** [delivered]: Q4 activity reflects continued wind‑down of these programs. - **Infinity merger termination** [delivered]: Merger agreement with Infinity Pharmaceuticals was terminated; company now operating as standalone. ### Fears / risks - **Clinical risk**: Early‑stage data readouts are pending and efficacy thresholds (e.g., 20% PFS) are uncertain. - **Regulatory risk**: Approval pathways for novel mechanisms (CDK9 inhibition, mitochondrial inhibition) remain unproven. - **Financial risk**: Cash runway is limited to ~12 months; any delay in data could strain liquidity. - **Stockholder activism**: Activist investors Anson and Cable Car have submitted director candidates, creating governance pressure. - **Revenue risk**: Current revenue is solely from existing collaborations and is not expected to continue. - **Safety risk**: Pneumonitis observed in early voruciclib dosing required schedule changes. - **Competitive risk**: Both programs target mechanisms with emerging competitors and may face market adoption challenges. - **Execution risk**: Program timelines depend on patient enrollment and biomarker validation, which could cause delays. ### Key quotes > “we're committed to pursuing our two promising clinical stage programs as a standalone company.” > “we see important opportunities in the continued progress of our two clinical stage oncology programs, voruciclib and ME-344.” > “All the revenue we're recognizing is all KKC driven from our collaboration with them, so it's not anticipated to continue into the future.” — Richard Ghalie ## Quarter one-liners - **2023 Q4:** MEI Pharma, after terminating its Infinity merger, is focused on two early‑stage oncology candidates—voruciclib and ME‑344—with data readouts slated for early 2024 and a cash runway of at least 12 months, while navigating stockholder activism and early‑phase clinical risk. - **2022 Q4:** MEI Pharma ends FY2022 with $153M cash, advances zandelisib Phase 3 COASTAL after FDA's Project FrontRunner ends accelerated approval via single-arm studies; TIDAL data shows 70.3% ORR; pipeline includes voruciclib and ME-344 combos. - **2021 Q4:** — - **2020 Q4:** MEI Pharma ends FY2020 with strong cash, progress on zandelisib and a Kyowa Kirin partnership, but enrollment and COVID‑related timing uncertainties linger for key trials. - **2019 Q4:** MEI Pharma ended FY2019 with $79.8M cash and no debt, advancing four oncology candidates; ME-401 Phase 2 enrollment ongoing for 3L follicular lymphoma targeting accelerated approval, voruciclib in Phase 1/2 with venetoclax, and strategic partnerships with BeiGene and Kyowa Kirin. - **2018 Q4:** MEI Pharma ended FY2018 with $102.7M cash, no debt, advancing four clinical candidates and planning a Phase II accelerated‑approval study for ME‑401, while noting higher upcoming clinical spend. - **2017 Q4:** — ## Theme arcs - **Management tone** (improving): Δ mgmt=+0.60 ## Fear persistence - **regulatory risk** [recurring]: 2018 Q4, 2023 Q4 - **competition** [recurring]: 2018 Q4, 2019 Q4 - **enrollment risk** [resolved]: 2018 Q4 - **financial risk** [recurring]: 2018 Q4, 2023 Q4 - **toxicity risk** [resolved]: 2018 Q4 - **data readout risk** [resolved]: 2018 Q4 - **partnership risk** [resolved]: 2018 Q4 - **clinical trial execution** [resolved]: 2019 Q4 - **regulatory pathway** [resolved]: 2019 Q4 - **commercialization strategy** [resolved]: 2019 Q4 ## Guidance path 2017 Q4:vague → 2018 Q4:vague → 2019 Q4:vague → 2020 Q4:maintained → 2021 Q4:vague → 2022 Q4:vague → 2023 Q4:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/LITS`